A Study of the Effects of LY3372689 on the Brain in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 8, 2019

Primary Completion Date

February 19, 2020

Study Completion Date

February 19, 2020

Conditions

Healthy

Interventions

DRUG

LY3372689

Administered orally.

DIAGNOSTIC_TEST

[18F]LSN3316612

Administered IV.

Trial Locations (1)

Invicro, Institute for Neurodegenerative Disorders, New Haven

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT03944031 - A Study of the Effects of LY3372689 on the Brain in Healthy Participants | Biotech Hunter | Biotech Hunter